- Oops!Something went wrong.Please try again later.
MENLO PARK, Calif., Jan. 22, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases and extend healthy lifespan, announces the appointment of Jordyn Tarazi as Director of Investor Relations. In this newly created role, Ms. Tarazi is responsible for developing, implementing and leading a strategic global investor relations program for CohBar.
“With her investment banking and biotechnology investor relations background, Jordyn will play a key role in raising awareness of our company as we continue to ramp up our efforts, both clinically and preclinically, to develop novel therapeutics for chronic diseases,” said Steven Engle, Chief Executive Officer. “We are very pleased to welcome Jordyn and anticipate she will be a strong addition to the CohBar team.”
“I am delighted to join CohBar at such an exciting time for the company,” commented Ms. Tarazi. “I look forward to building a world-class investor relations program and working with the team to communicate to key stakeholders the evolving story of CohBar’s unique mitochondrial peptide platform as a source for potential novel therapeutics.”
Ms. Tarazi has over 10 years of public company investor relations experience. Before joining CohBar, Ms. Tarazi was the Director of Investor Relations at Fluent, a NASDAQ listed marketing services company, where she built a large institutional following and sell side research coverage while guiding the narrative through periods of significant change. Previously, she was the Director of Investor Relations at OncoSec Medical, a NASDAQ listed immuno-oncology company, where she built an investor relations program that attracted top healthcare institutions, analysts and media. She started her career at Rodman & Renshaw where she helped grow the global institutional investor base for publicly traded companies before moving to H.C. Wainwright & Co., where she aided in the development of corporate access capabilities and in the fundraising efforts for publicly traded companies. Ms. Tarazi graduated Summa Cum Laude from DePaul University.
CohBar (CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar’s founders of a novel group of naturally occurring mitochondrial-derived peptides within the mitochondrial genome that regulate metabolism and cell death, and whose biological activity declines with age. To date, the company has discovered more than 100 mitochondrial-derived peptides. CohBar’s efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, fibrotic diseases, cancer, type 2 diabetes, and cardiovascular and neurodegenerative diseases. The company’s lead compound, CB4211, is in the phase 1b stage of a phase 1a/1b clinical trial that includes an evaluation of biological activity relevant to NASH and obesity.
For additional company information, please visit www.cohbar.com.
This news release contains forward-looking statements which are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “should,” “would,” “project,” “plan,” “expect,” “goal,” “seek,” “future,” “likely” or the negative or plural of these words or similar expressions. Examples of such forward-looking statements including but not limited to statements regarding anticipated outcomes of research and clinical trials for our mitochondria based therapeutic (MBT) candidates; expectations regarding the growth of MBTs as a significant future class of drug products; and statements regarding anticipated therapeutic properties and potential of our mitochondrial peptide analogs and MBTs.
You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include: our ability to successfully advance drug discovery and development programs, including the delay or termination of ongoing clinical trials; our possible inability to mitigate the prevalence and/or persistence of the injection site reactions, receipt of unfavorable feedback from regulators regarding the safety or tolerability of CB4211 or the possibility of other developments affecting the viability of CB4211 as a clinical candidate or its commercial potential; results that are different from earlier data results including less favorable than and that may not support further clinical development; our ability to raise additional capital when necessary to continue our operations; our ability to recruit and retain key management and scientific personnel; the risk that our intellectual property may not be adequately protected; and our ability to establish and maintain partnerships with corporate and industry partners. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.
Director of Investor Relations
LifeSci Advisors, LLC